The RNA helicase p68 is a novel androgen receptor coactivator involved in splicing and is overexpressed in prostate cancer

  1. Lookup NU author(s)
  2. Dr Emma Clark
  3. Dr Anne Coulson
  4. Caroline Dalgliesh
  5. Dr Prabhakar Rajan
  6. Dr Rakesh Heer
  7. Dr Luke Gaughan
  8. Professor Hing Leung
  9. Professor David Elliott
  10. Professor Craig Robson
Author(s)Clark EL, Coulson AC, Dalgliesh C, Rajan P, Nicol SM, Fleming S, Heer R, Gaughan L, Leung HY, Elliott DJ, Fuller-Pace FV, Robson CN
Publication type Article
JournalCancer Research
Year2008
Volume68
Issue19
Pages7938-7946
ISSN (print)0008-5472
ISSN (electronic)1538-7445
Full text for this publication is not currently held within this repository. Alternative links are provided below where available.
The androgen receptor (AR) is a member of the nuclear steroid hormone receptor family and is thought to play an important role in the development of both androgen-dependent and androgen-independent prostatic malignancy. Elucidating roles by which cofactors regulate AR transcriptional activity may provide therapeutic advancement for prostate cancer (PCa). The DEAD box RNA helicase p68 (Ddx5) was identified as a novel AR-interacting protein by yeast two-hybrid screening, and we sought to examine the involvement of p68 in AR signaling and PCa. The p68-AR interaction was verified by colocalization of overexpressed protein by immunofluorescence and confirmed in vivo by coimmunoprecipitation in the PCa LNCaP cell line. Chromatin immunoprecipitation in the same cell line showed AR and p68 recruitment to the promoter region of the androgen-responsive prostate-specific antigen (PSA) gene. Luciferase reporter, minigene splicing assays, and RNA interference (RNAi) were used to examine a functional role of p68 in AR-regulated gene expression, whereby p68 targeted RNAi reduced AR-regulated PSA expression, and p68 enhanced AR-regulated repression of CD44 splicing (P = 0.008). Tyrosine phosphorylation of p68 was found to enhance coactivation of ligand-dependent transcription of AR-regulated luciferase reporters independent of ATP-binding. Finally, we observe increased frequency and expression of p68 in PCa compared with benign tissue using a comprehensive prostate tissue microarray (P = 0.003; P = 0.008). These findings implicate p68 as a novel AR transcriptional coactivator that is significantly overexpressed in PCa with a possible role in progression to hormone-refractory disease.
PublisherAmerican Association for Cancer Research
URLhttp://dx.doi.org/10.1158/0008-5472.CAN-08-0932
DOI10.1158/0008-5472.CAN-08-0932
Actions    Link to this publication